SCHEMBL120734

SCHEMBL120734

COc1ccc(NC(=O)COc2c(C)cc(-c3nc4cc(OC)cc(OC)c4c(=O)[nH]3)cc2C)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 13/20 0.66
HDAC1 Q13547 10/20 0.66
HDAC3 O15379 8/20 0.65
HDAC4 P56524 8/20 0.65
HDAC7 Q8WUI4 8/20 0.65
HDAC2 Q92769 8/20 0.65
HDAC10 Q969S8 8/20 0.65
HDAC11 Q96DB2 8/20 0.65
HDAC8 Q9BY41 8/20 0.65
HDAC6 Q9UBN7 8/20 0.65
HDAC9 Q9UKV0 8/20 0.65
HDAC5 Q9UQL6 8/20 0.65
PARP1 P09874 2/20 0.61
BRD2 P25440 2/20 0.59
CSNK1A1 P48729 1/20 0.59
CSNK1D P48730 1/20 0.59
CSNK1E P49674 1/20 0.59
CSNK1G2 P78368 1/20 0.59
BRD3 Q15059 1/20 0.59
CSNK1G1 Q9HCP0 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30433788 1.00 BRD4 (0.66) BRD4HDAC1HDAC3HDAC4HDAC7
SCHEMBL120733 0.88 BRD4 (0.71) BRD4HDAC1HDAC3HDAC4HDAC7
SCHEMBL30434379 0.88 BRD4 (0.71) BRD4HDAC1HDAC3HDAC4HDAC7
SCHEMBL348174 0.86 BRD4 (0.65) BRD4HDAC1HDAC3HDAC4HDAC7
SCHEMBL30053052 0.85 BRD4 (0.69) BRD4HDAC1HDAC3HDAC4HDAC7
SCHEMBL147114 0.85 BRD4 (0.69) BRD4HDAC1HDAC3HDAC4HDAC7
SCHEMBL122144 0.84 BRD4 (0.64) BRD4HDAC1HDAC3HDAC4HDAC7
SCHEMBL30435049 0.84 BRD4 (0.64) BRD4HDAC1HDAC3HDAC4HDAC7
SCHEMBL149455 0.84 BRD4 (0.70) BRD4HDAC1HDAC3HDAC4HDAC7
SCHEMBL30434669 0.84 BRD4 (0.70) BRD4HDAC1HDAC3HDAC4HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3431086-B1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP (CA) 2020-06-17 EP claimed
US-20200129512-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2020-04-30 US claimed
EP-3431086-A1 NOVEL ANTI-INFLAMMATORY AGENTS Resverlogix Corp. (CA) 2019-01-23 EP claimed
EP-2421533-B1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP (CA) 2018-10-17 EP claimed
US-20170333419-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2017-11-23 US claimed
US-9757368-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2017-09-12 US claimed
US-20130281398-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION RVX THERAPEUTICS INC. (CA) 2013-10-24 US claimed
US-20120059002-A1 NOVEL ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2012-03-08 US claimed
EP-2421533-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2012-02-29 EP claimed
WO-2010123975-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2010-10-28 WO claimed
CN-107252429-B Novel anti-inflammatory agent 雷斯韦洛吉克斯公司 2023-06-16 CN disclosed
EP-3431086-B1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP (CA) 2020-06-17 EP disclosed
US-20200129512-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2020-04-30 US disclosed
US-20200129512-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2020-04-30 US disclosed
EP-3431086-A1 NOVEL ANTI-INFLAMMATORY AGENTS Resverlogix Corp. (CA) 2019-01-23 EP disclosed
US-20120059002-A1 NOVEL ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2012-03-08 US disclosed
US-20120059002-A1 NOVEL ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2012-03-08 US disclosed
EP-2421533-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2012-02-29 EP disclosed
WO-2010123975-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2010-10-28 WO disclosed
WO-2010123975-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059002-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 BRD4 192/4885HDAC1 639/4885HDAC3 1622/4885
US-20130281398-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION PHKB, BAZ2A, EP300 BRD4 10/4885HDAC1 30/4885HDAC3 54/4885
US-20170333419-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 BRD4 192/4885HDAC1 639/4885HDAC3 1622/4885
US-20200129512-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 BRD4 192/4885HDAC1 639/4885HDAC3 1622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.